API
Levofloxacin Hydrate
KDMF APIs
Levofloxacin Hydrate
Korean name | 레보플로사신수화물 |
|---|---|
Category | Sensory organs |
CAS No. | 100986-85-4 |
KDMF registration No. | 20100414-102-F-50-10(10) |
Manufacturer | Zhejiang East-asia Pharmaceutical Co., Ltd. |
Specification | USP |
Product information
IUPAC Name | (2S)-7-fluoro-2-methyl-6-(4-methylpiperazin-1-yl)-10-oxo-4-oxa-1-azatricyclo[7.3.1.0⁵,¹³]trideca-5(13),6,8,11-tetraene-11-carboxylic acid |
|---|---|
Synonyms | (-)-Ofloxacin (3S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzoxazine-6-carboxylic acid (S)-(-)-9-fluoro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-2,3-dihydro-7H-pyrido[1,2,3-de][1,4]benzooxazine-6-carboxylic acid (S)-9-Fluoro-2,3-dihydro-3-methyl-10-(4-methyl-1-piperazinyl)-7-oxo-7H-pyrido(1,2,3-de)-1,4-benzoxazine-6-carboxylic acid (S)-Ofloxacin L-Ofloxacin Levofloxacin |
Description | Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin . It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer).Levofloxacin, along with other quinolones such as gatifloxacin and moxifloxacin , is a member of the third generation of fluoroquinolones, colloquially referred to as the "respiratory quinolones" due to improved activity against gram-positive bacteria commonly implicated in respiratory infections. Levofloxacin was first approved by the FDA in 1996, and was approved in Canada and several South American countries soon after. |
Certificate of Analysis | If you need more information, please contact us. |
If you need additional documents such as specifications or certificates of analysis, please request them together with your inquiry. Our team will review and reply. (02-579-1056 · ace@acebiopharm.com)